Fulgent Genetics, Inc. — Form 8-K
Filed July 30, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 52/100
What the filing says
Fulgent reported Q2 2026 revenue of $85.4M, up 20.1% sequentially but only 4.4% YoY. GAAP net loss was $(29.5)M ($(1.05)/share); non-GAAP loss was $(16.2)M ($(0.58)/share). Company repurchased 1.5M shares for $23.8M in Q2. Full-year 2026 revenue guidance was reduced to $330–340M (from prior implied guidance), with non-GAAP loss of $(63)–$(67)M expected. CFO cited processing delays in revenue-cycle billing-system transition impacting collections. Cash position strong at $551.5M (excluding anticipated $106.1M tax refund). Therapeutics pipeline includes Phase 2 FID-007 (HNSCC) showing 61.9% ORR, and Phase 1 FID-022 progressing.
Why this rating
Revenue guidance cut ~5% is material for ~$284M market-cap company; operational/billing issues are worrying. Strong cash cushions risk. Pharma pipeline encouraging but pre-commercial.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.